DNA damage is an important mechanism of glioma. X-ray cross-complementing group 1 (XRCC1) is a DNA repair gene that participates in the base excision repair pathway. To date, many studies have been performed to investigate the association between the XRCC1 polymorphisms and risk of cancers such as breast cancer, and gastroesophageal cancer, but the number of studies that focused on glioma is relatively small. Evidence regarding the role of the single nucleotide polymorphisms in XRCC1 as genetic markers for glioma risk is inconsistent. Prof. Xinquan Gu and team from China-Japan Union Hospital of Jilin University, China performed a meta-analysis to identify statistical evidence for an association between the XRCC1 Arg399Gln, Arg194Trp, Arg280His polymorphisms and glioma risk by accumulating all published data. Meta-analysis results verified that the XRCC1 Arg399Gln polymorphism may be a biomarker of glioma susceptibility, especially in Asian populations. The Arg194Trp and Arg280His polymorphisms were found not to be associated with overall glioma risk. These findings, published in the Neural Regeneration Research (Vol. 8, No. 26, 2013), provide the necessary scientific basis for the glioma pathogenesis and glioma risk population screening.
|Contact: Meng Zhao|
Neural Regeneration Research